BCRX BioCryst Pharmaceuticals Inc.

1.91
-0.08  -4%
Previous Close 1.99
Open 1.94
Price To Book 7.64
Market Cap 294,506,626
Shares 154,191,951
Volume 2,676,202
Short Ratio
Av. Daily Volume 6,190,467
Stock charts supplied by TradingView

NewsSee all news

  1. BEROTRALSTAT (BCX7353) SIGNIFICANTLY REDUCED USE OF ACUTE ON-DEMAND MEDICINE IN HAE PATIENTS IN APEX-2

    RESEARCH TRIANGLE PARK, N.C., March 16, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced new data from the APeX-2 trial showing 150 mg of oral, once-daily berotralstat (BCX7353) for

  2. BioCryst Reports Fourth Quarter and Full Year 2019 Financial Results and Upcoming Key Milestones

    —Berotralstat NDA accepted by FDA; PDUFA date December 3, 2020— —JNDA accepted by PMDA under Sakigake timeline; approval expected 2H 2020— —PNH proof of concept data with oral Factor D inhibitor, BCX9930, expected 2Q

  3. BioCryst Begins Proof of Concept Trial in PNH Patients With Oral Factor D Inhibitor, BCX9930

    RESEARCH TRIANGLE PARK, N.C., March 05, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the first patients have been dosed with BCX9930 in a proof of concept trial in paroxysmal

  4. BioCryst to Present at Barclays Global Healthcare Conference

    RESEARCH TRIANGLE PARK, N.C., March 03, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the company will present at the Barclays Global Healthcare Conference in Miami Beach,

  5. BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

    RESEARCH TRIANGLE PARK, N.C., March 02, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted 10 newly-hired

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Approved September 21, 2017.
RAPIVAB (peramivir injection)
Acute uncomplicated influenza to pediatric patients
PDUFA date December 3, 2020
Berotralstat BCX7353
Reduce or eliminate attacks in HAE patients
Phase 2b data released February 2016 - primary endpoint not met
BCX4161 - OPuS-2
Hereditary angioedema
Approved Dec 22 2014
RAPIVAB (peramivir)
INFLUENZA ACUTE
Phase 1 trial completion announced May 9, 2019. Generally safe and well tolerated.
Galidesivir
Healthy volunteers
Phase 1 data due 2Q 2020.
BCX9930
Paroxysmal nocturnal hemoglobinuria (PNH)
Phase 1 data due 2H 2020.
BCX9250
Fibrodysplasia ossificans progressiva (FOP)

Latest News

  1. BEROTRALSTAT (BCX7353) SIGNIFICANTLY REDUCED USE OF ACUTE ON-DEMAND MEDICINE IN HAE PATIENTS IN APEX-2

    RESEARCH TRIANGLE PARK, N.C., March 16, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced new data from the APeX-2 trial showing 150 mg of oral, once-daily berotralstat (BCX7353) for

  2. BioCryst Reports Fourth Quarter and Full Year 2019 Financial Results and Upcoming Key Milestones

    —Berotralstat NDA accepted by FDA; PDUFA date December 3, 2020— —JNDA accepted by PMDA under Sakigake timeline; approval expected 2H 2020— —PNH proof of concept data with oral Factor D inhibitor, BCX9930, expected 2Q

  3. BioCryst Begins Proof of Concept Trial in PNH Patients With Oral Factor D Inhibitor, BCX9930

    RESEARCH TRIANGLE PARK, N.C., March 05, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the first patients have been dosed with BCX9930 in a proof of concept trial in paroxysmal

  4. BioCryst to Present at Barclays Global Healthcare Conference

    RESEARCH TRIANGLE PARK, N.C., March 03, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the company will present at the Barclays Global Healthcare Conference in Miami Beach,

  5. BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

    RESEARCH TRIANGLE PARK, N.C., March 02, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted 10 newly-hired

  6. BioCryst to Present New Data at American Academy of Allergy, Asthma & Immunology Annual Meeting

    RESEARCH TRIANGLE PARK, N.C., Feb. 27, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the company will present abstracts with new data on berotralstat (BCX7353), an oral,

  7. BioCryst Appoints Alan G. Levin to Board of Directors

    RESEARCH TRIANGLE PARK, N.C., Feb. 25, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the company has appointed former Pfizer chief financial officer (CFO), Alan G. Levin,

  8. BioCryst to Report Fourth Quarter and Full Year 2019 Financial Results on March 5

    RESEARCH TRIANGLE PARK, N.C., Feb. 20, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the company will report its fourth quarter and full year 2019 financial results on

  9. FDA Accepts BioCryst's NDA for Oral, Once Daily Berotralstat (BCX7353) to Prevent HAE Attacks

    RESEARCH TRIANGLE PARK, N.C., Feb. 18, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced that the U.S. Food and Drug Administration (FDA) has accepted and filed its new drug application

  10. BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    RESEARCH TRIANGLE PARK, N.C., Feb. 06, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted five newly-hired

  11. BioCryst Submits Japanese New Drug Application for Oral, Once Daily Berotralstat

    RESEARCH TRIANGLE PARK, N.C., Feb. 03, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that it has submitted a new drug application (JNDA) to the Japanese Pharmaceuticals and

  12. BioCryst Strengthens Commercial Rare Disease Leadership

    RESEARCH TRIANGLE PARK, N.C., Jan. 15, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the appointments of Charles Gayer as chief commercial officer and Allen Hodge as vice

  13. BioCryst to Provide Berotralstat and BCX9930 Program Updates at 38th Annual J.P. Morgan Healthcare Conference

    RESEARCH TRIANGLE PARK, N.C., Jan. 12, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will provide updates on berotralstat, an oral kallikrein inhibitor for

  14. BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

    RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted two newly-hired

  15. BioCryst to Present at 38th Annual J.P. Morgan Healthcare Conference

    RESEARCH TRIANGLE PARK, N.C., Jan. 03, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the company will present at the 38th Annual J.P. Morgan Healthcare Conference in San

  16. BioCryst Submits New Drug Application for Oral, Once Daily Berotralstat (BCX7353) to Prevent HAE Attacks

    RESEARCH TRIANGLE PARK, N.C., Dec. 11, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced it has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for

  17. BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    RESEARCH TRIANGLE PARK, N.C., Dec. 04, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted five newly-hired

  18. BioCryst Announces Full Exercise of Underwriters' Option to Purchase Additional Shares and Completion of Public Offering of Common Stock

    RESEARCH TRIANGLE PARK, N.C., Nov. 18, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today the completion of an underwritten public offering of 43,620,690 shares of its common stock,

  19. BioCryst to Present at Upcoming Investor Conferences

    RESEARCH TRIANGLE PARK, N.C., Nov. 14, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the company will present at the Jefferies London Healthcare Conference on Thursday,

  20. BioCryst Prices Public Offering of Common Stock

    RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today the pricing of an underwritten public offering of 37,931,035 shares of its common stock,

  21. BioCryst Commences Public Offering of Common Stock

    RESEARCH TRIANGLE PARK, N.C., Nov. 12, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that it is offering to sell $55 million of its common stock in an underwritten public

  22. Biocryst to Present Abstracts at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology

    RESEARCH TRIANGLE PARK, N.C., Nov. 07, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the company will present two abstracts at the upcoming Annual Scientific Meeting of the

  23. BioCryst Reports Third Quarter 2019 Financial Results and Upcoming Key Milestones

    —New drug application for oral, once-daily BCX7353 for prevention of hereditary angioedema attacks on-track for submission to FDA in Q4 2019— —Data from proof of concept study in PNH patients with oral Factor D

  24. New Clinical Trial Results and Market Research Support Significant Commercial Opportunity for Oral, Once Daily BCX7353 in HAE

    —Results of the APeX-S and APeX-2 trials show patients taking 150 mg of oral, once daily BCX7353 achieved a stable average attack rate of ≤ 1 attack per month at 48 weeks— —75 percent of patients taking 150 mg BCX7353

  25. BioCryst Announces Partnership With Torii Pharmaceutical to Commercialize BCX7353 in Japan for the Prevention of HAE Attacks

    —Agreement includes up to $42 million of upfront and potential milestone payments plus royalties on net sales— —JNDA submission to PMDA on track for Q1 2020— —Deal leverages Torii's proven track record to deliver

  26. BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    RESEARCH TRIANGLE PARK, N.C., Nov. 04, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted five newly-hired

  27. BioCryst Begins Phase 1 Trial With BCX9250, an Oral ALK-2 Inhibitor, for Treatment of Fibrodysplasia Ossificans Progressiva

    —BCX9250 significantly suppressed heterotrophic ossification in preclinical studies— —Urgent medical need with no approved treatments for FOP — —Phase 1 data expected in 2H 2020— RESEARCH TRIANGLE PARK, N.C., Nov.

  28. BioCryst Reports Data From Phase 1 Trial of BCX9930 and Announces Plans to Advance Program Into Proof of Concept Study in PNH Patients

    —Phase 1 data showed rapid, sustained and >95% inhibition of alternative pathway of complement system with 100 mg of oral BCX9930 BID— —BCX9930 safe and generally well tolerated— —Part 1 SAD and part 2 MAD data

  29. BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    RESEARCH TRIANGLE PARK, N.C., Oct. 03, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted three newly-hired

  30. U.S. Government Exercises Option for Additonal Rapivab® for Strategic National Stockpile

    RESEARCH TRIANGLE PARK, N.C., Sept. 26, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the U.S. Department of Health and Human Services (HHS) has exercised its option to

  31. BioCryst Pharmaceuticals to Present at Cantor Global Healthcare Conference

    RESEARCH TRIANGLE PARK, N.C., Sept. 24, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the company will present at the Cantor Global Healthcare Conference in New York on

  32. BioCryst Appoints Helen Thackray, M.D., to Board of Directors

    RESEARCH TRIANGLE PARK, N.C., Sept. 23, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the company has appointed clinical rare disease expert, Helen Thackray, M.D., FAAP, to

  33. BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    RESEARCH TRIANGLE PARK, N.C., Sept. 04, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted five newly-hired

  34. BioCryst to Present at H.C. Wainwright Global Investment Conference

    RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the company will present at the H.C. Wainwright Global Investment Conference in New